<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30713">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706886</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-GO1-001</org_study_id>
    <nct_id>NCT02706886</nct_id>
  </id_info>
  <brief_title>Study of ALN-GO1 in Healthy Adult Subjects and Patients With Primary Hyperoxaluria Type 1</brief_title>
  <official_title>A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of single- and multiple-ascending doses of ALN-GO1 in healthy adult
      volunteers and subjects with PH1.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of ALN-GO1 evaluated by the proportion of subjects experiencing adverse events (AEs)</measure>
    <time_frame>Part A (SAD phase): Up to 181 days; Part B (MAD phase): Up to 321 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-GO1</measure>
    <time_frame>Part A (SAD phase): Up to 2 days; Part B (MAD phase): Up to 141 days</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-GO1</measure>
    <time_frame>Part A (SAD phase): Up to 2 days; Part B (MAD phase): Up to 141 days</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-GO1</measure>
    <time_frame>Part A (SAD phase): Up to 2 days; Part B (MAD phase): Up to 141 days</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-GO1</measure>
    <time_frame>Part A (SAD phase): Up to 2 days; Part B (MAD phase): Up to 141 days</time_frame>
    <description>tÂ½</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ALN-GO1 on plasma glycolate concentration</measure>
    <time_frame>Part A (SAD phase): Up to 181 days; Part B (MAD phase): Up to 321 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ALN-GO1 on urinary glycolate excretion</measure>
    <time_frame>Part B (MAD phase): Up to 321 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ALN-GO1 on urinary oxalate excretion</measure>
    <time_frame>Part B (MAD phase): Up to 321 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Hyperoxaluria Type 1 (PH1)</condition>
  <arm_group>
    <arm_group_label>ALN-GO1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-GO1</intervention_name>
    <description>Single or multiple doses of ALN-GO1 by subcutaneous (sc) injection</description>
    <arm_group_label>ALN-GO1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Parts A and B:

          -  Women of child bearing potential must have a negative pregnancy test, cannot be
             breastfeeding, and must be willing to use contraception.

          -  Willing to provide written informed consent and to comply with study requirements.

        Additional Inclusion Criteria for Part B:

          -  Confirmation of PH1 disease

          -  Meet 24 hour urine oxalate excretion requirements

          -  Estimated GFR of &gt;45 mL/min/1.73m2.

          -  If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90
             days

        Exclusion Criteria for Parts A and B:

          -  No clinically significant health concerns (with the exception of PH1 for patients in
             Part B)

          -  Clinically significant ECG abnormalities

          -  Abnormal for AST/ALT and any other clinical safety laboratory result considered
             clinically significant

          -  Received an investigational agent within 3 months before the first dose of study drug
             or are in follow-up of another clinical study

          -  Known history of allergic reaction to an oligonucleotide or GalNAc

          -  History of intolerance to subcutaneous injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Haslett, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trials Hotline Call for Complete Site List</last_name>
    <phone>617-575-7400</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trials Hotline Call for Complete Site List</last_name>
    <phone>1-866-330-0326</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>March 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PH1</keyword>
  <keyword>Primary Hyperoxaluria</keyword>
  <keyword>RNAi therapeutic</keyword>
  <keyword>siRNA</keyword>
  <keyword>AGT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
